Istradefylline
Back to searchMolecule Structure
Scientific Name
Istradefylline
Description of the Drug
Istradefylline is a selective adenoside A2A receptor antagonist indicated in adjunct to levodopa and carbidopa for the treatment of Parkinson’s Disease.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB11757
http://www.drugbank.ca/drugs/DB11757
Brand Name(s)
Nourianz
Company Owner(s)
Kyowa Kirin Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Adenosine A2a receptor | SINGLE PROTEIN | ANTAGONIST | CHEMBL251 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL633262 | |
| DrugBank | DB11757 | |
| PubChem: Thomson Pharma | 14878146 | |
| PubChem | 5311037 | |
| Nikkaji | J2.888.328E | J1.018.438J |
| BindingDB | 50176050 | |
| EPA CompTox Dashboard | DTXSID7057652 | |
| DrugCentral | 4882 | |
| Brenda | 39744 | |
| ChemicalBook | CB11261287 | |
| Guide to Pharmacology | 5608 | |
| rxnorm | ISTRADEFYLLINE | NOURIANZ |
| PubChem: Drugs of the Future | 12014869 | |
| ChEBI | 134726 | |
| ZINC | ZINC000003803921 |
